Evidence map›Paper›PMID 37573343›Full record

ReviewBMC oral health2023

Metastasising ameloblastoma or ameloblastic carcinoma? A case report with mutation analyses.

Pavel Hurník, Barbora Moldovan Putnová, Tereza Ševčíková, Eva Hrubá, Iveta Putnová, Josef Škarda, Martin Havel, Oldřich Res, Jakub Cvek, Marcela Buchtová and 1 more

Open access · goldAbstract readReviewCase Reports
In one paragraph

Review in BMC oral health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Pavel HurníkLaboratory of Molecular Morphogenesis, Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Brno, Czech Republic.
Barbora Moldovan PutnováLaboratory of Molecular Morphogenesis, Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Brno, Czech Republic.
Tereza ŠevčíkováDepartment of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Eva HrubáLaboratory of Molecular Morphogenesis, Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Brno, Czech Republic.
Iveta PutnováLaboratory of Molecular Morphogenesis, Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Brno, Czech Republic.
Josef ŠkardaInstitute of Clinical and Molecular Pathology and Medical Genetics, Faculty Hospital and Medical Faculty Ostrava, Ostrava, Czech Republic.
Martin HavelDepartment of Nuclear Medicine, University Hospital Ostrava, Ostrava, Czech Republic.
Oldřich ResDepartment of Oral and Maxillofacial Surgery, University Hospital Ostrava, Ostrava, Czech Republic.
Jakub CvekDepartment of Oncology, Faculty of Medicine and University Hospital Ostrava, Ostrava, Czech Republic.
Marcela BuchtováLaboratory of Molecular Morphogenesis, Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Brno, Czech Republic. buchtova@iach.cz.ORCID http://orcid.org/0000-0002-0262-6774
Jan ŠtembírekLaboratory of Molecular Morphogenesis, Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Brno, Czech Republic. stembirek@iach.cz.
Czech Academy of Sciences · CZUniversity Hospital Ostrava · CZUniversity Hospital Olomouc · CZUniversity of Ostrava · CZUniversity of Veterinary Sciences Brno · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmeloblastic carcinoma and metastasising ameloblastoma are rare epithelial odontogenic tumours with aggressive features. Distinguishing between these two lesions is often clinically difficult but necessary to predict tumour behaviour or to plan future therapy. Here, we provide a brief review of the literature available on these two types of lesions and present a new case report of a young man with an ameloblastoma displaying metastatic features. We also use this case to illustrate the similarities and differences between these two types of tumours and the difficulties of their differential diagnosis. CASE PRESENTATION: Our histopathological analyses uncovered a metastasising tumour with features of ameloblastic carcinoma, which developed from the ameloblastoma. We profiled the gene expression of Wnt pathway members in ameloblastoma sample of this patient, because multiple molecules of this pathway are involved in the establishing of cell polarity, cell migration or for epithelial-mesenchymal transition during tumour metastasis to evaluate features of tumor behaviour. Indeed, we found upregulation of several cell migration-related genes in our patient. Moreover, we uncovered somatic mutation BRAF p.V600E with known pathological role in cancerogenesis and germline heterozygous FANCA p.S858R mutation, whose interpretation in this context has not been discussed yet.

conclusionsIn conclusion, we have uncovered a unique case of ameloblastic carcinoma associated with an alteration of Wnt signalling and the presence of BRAF mutation. Development of harmful state of our patient might be also supported by the germline mutation in one FANCA allele, however this has to be confirmed by further analyses.

Indexed as

AmeloblastomaCarcinomaOdontogenic TumorsHumansMaleMutationProto-Oncogene Proteins B-rafProto-Oncogene Proteins B-rafAmeloblastomaBenignBRAFCarcinomaCase reportFANCAMalignantMetastasizingWnt pathway

Identifiers

PMID37573343
PMCPMC10423427
OpenAlexW4385784044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.